(Sr.) Country Medical Manager (GI)

At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections,  where you are valued, accepted and respected for who you are, allowing you to thrive both personally and professionally. This is how we aim to prevent, stop and cure diseases and ensure everyone has access to healthcare today and for generations to come. Join Roche, where every voice matters.

The Position

Primary Purpose of Job (Job Summary)

The Country Medical Manager (CMM) is a trusted, externally focused, scientifically grounded partner within our customer engagement model. By building and maintaining deep and trusted connections with key top-tier customers over a meaningful period of time, the CMM will generate impact by anticipating and proactively optimizing medical practice, and ensure that Roche is a preferred partner in our key disease areas. 
The Medical function serves as a critical engine of competitiveness to ensure our innovations reach their full potential for patients with an end to end perspective. The role of the CMM is designed to maximize local and cross-country medical and scientific activities to accelerate the delivery of our pipeline, differentiate our portfolio based on data, drive strategic advocacy, community engagement, medical practice adoption, and access to our portfolio by proactively capitalizing on "Moments that Matter" across the asset lifecycle. 

Principle Roles & Responsibilities / Accountabilities

1. Contributing with Medical Expertise (core & common): 

• Medical Expertise: responsible for proactively contributing strong scientific, medical, and therapeutic area expertise within the relevant diseases informing differentiation of our pipeline and portfolio. Acting as a medical expert for the pipeline and portfolio throughout the product life cycle. 

• Shape Strategy: Lead the medical part of the integrated strategy, shape a forward-thinking, scientifically sound and differentiated value story locally and communicate Roche’s contributions across key disease areas, reflecting an end-to-end business perspective that pulls through the strategy with impact. 

2. Proactive Customer Engagement & Insights (core & common): 

• Proactive Targeted Medical Engagement: As a medical function our ambition is to spend the majority of our time proactively engaging with external customers as partners in the integrated customer engagement strategy. The CMM serves as the scientific and medical expert, proactively engaging top-tier TAEs, and other key stakeholders in full strategic and operational alignment with other in-field roles. In the pre-launch phase it is the priority to drive proactive E2E strategies that deliver superior experience, anticipate the future and shape medical practice accordingly. In the post-launch phase the engagement continues to ensure that the right patients are treated at the right time and the engagement scope expands on unserved patient populations. In-field engagement serves as a critical component of this overarching strategy for targeted scientific engagement. It is understood that based on business needs the CMM can serve as the primary point of contact for certain customers with the ambition to drive required healthcare system changes and where feasible earlier and broader adoption of our transformative portfolio.

• Medical Partnership & Education: Establish and maintain effective peer-to-peer relationships with external stakeholders and identify/develop science-driven collaborations withTAEs. Provide current, high-quality, integrated Medical Education plan and differentiating scientific information to external customers, support the scientific training of internal teams and ensure continuous education on medical knowledge for PPoC roles. Conduct high-quality, non-promotional International/National Scientific Exchanges to disseminate relevant data, foster physician confidence and clinical endorsement based on differentiating evidence and experience.

• Insight Generation: Based on aligned goals in the franchise team, the CMM should systematically conduct insight generation initiatives for responsible disease area/indication, including designing, collecting, analyzing, and translating external scientific and clinical practice insights (including patient perspectives) into strategic actionable and differentiating recommendations for the franchise team. Insights are secured in peer to peer discussions and via targeted medical activities. One of the medical activities involves medical/scientific advisory boards as a source of insights and strategic counsel.

3. License to operate & Operational Excellence (core & common):

• Adherence to Standards: Ensure all medical activities, including customer engagements, research projects, and material co-creation, are executed in line with company policies, procedures, and the highest compliance standards. This includes strict adherence to corporate policies, ethical behavior, local regulatory requirements as well as Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GVP).

4. Evidence Generation (Module Evidence Generation):
CMM acts as the navigators, guiding a disease area/asset through the complexities of development, launch, and post-launch phases. Steer the organization toward its goals, ensuring that all efforts are synchronized and aligned with the overarching strategy.

• Integrated Evidence Planning:

– Proactively involved in global integrated evidence plan (IEP) development in the initial stage to make sure China local practice reflected and fulfilled local regulatory and payers’ requirements to achieve market authorizations, reimbursement and value protection of our medicines/indications.
– Develop the local IEP, including a comprehensive local evidence gap analysis of required value narratives for the diverse set of healthcare system stakeholders, patients and caregivers. This analysis is crucial to inform global and cross-country opportunities and identify remaining requirements for local evidence to support medical practice adoption, access and continuous value demonstration across the asset life cycle. Strategic decision making, portfolio prioritization and resource allocation is to follow accordingly.

• Evidence Strategy Implementation: Contribute directly to the local evidence strategy, proactively identifying local differentiating evidence gaps, and facilitating the development and implementation of differentiating tactics to address the prioritized gaps, specifically to ensure, maintain and broaden access to our portfolio. These differentiating tactics include leading or supporting Interventional Studies (IS), Non-Interventional Studies (NIS), externally submitted Investigator-Initiated Studies (IIS) with a relevant strategic fit, and Real-World Evidence/Data (RWE/RWD) studies, scientific projects and other activities.

• Clinical Development Support

– Identify the key TAEs to provide insights into the disease burden, the patient pathway, patient needs and preferences, current treatment landscape and potential shifting in standard of care, to understand external needs and develop optimal company evidence generation strategies and action plans that are relevant for patients or society.
– Collaborate closely with Clinical Operations (PDG) and Legal/Regulatory (LEG) teams to provide support for Phase I-IV clinical studies when needed. This includes partnering with PDG for site engagement such as proactive input on feasibility and strategic site selection, participating in selected SIVs providing essential medical expertise and relevant knowledge to aid in study execution in collaboration with GMCL (Global Medical Collaboration Leader) and / or other functions as applicable per local agreement. For selected sites (global most valuable customers) take an active role in the OneRoche (g/pRED, PD, GPS, Affiliate, PT, Diagnostics) E2E holistic customer experience loop. Ensure that key insights from investigators, study coordinators and nurses are brought into the strategic planning of “how to go to market” and the local IEP gap analysis.

5. Focusing on Patient Impact and driving the value story in the HTA process (Module HTA)

• Maximizing HTA Value: Contribute scientific and medical expertise to local Health Technology Assessment (HTA) submissions and interactions, ensuring critical appraisal mindset on our data packages with good statistical understanding and by discussing the evidence for its transferability to the real-world healthcare setting. CMM should lead a holistic evidence generation strategy to support market access to articulate the differentiating value story of our innovations in the local context to secure patient access.

– CMM ensures early insights are used to generate local IEP/local gap analysis so data generation nitiatives support the HTA value package locally. CMM validates the data's scientific integrity and, through additional stakeholder exchange (TAEs/societies), ensures the HTA submission is clinically relevant and credible.

• Shaping Medical Practice: In parallel with the development of strategic partnerships with external customers to shape medical practice and drive the adoption of medical innovations, a core focus of the role is the systematic collection of insights, as well as the identification and addressing of medical and customer needs. These insights will serve to inform and guide the development or localization of the Disease Area (DA) company’s strategy. This includes contextualizing AI information with internal and external stakeholders as new technologies will disrupt the role of medical professionals.

6. Pipeline Product Strategic Contribution / Shaping (Module Pipeline):
– Drive customer advocacy and lasting preference through proactive E2E strategies that deliver superior experience, anticipate the future & shape medical practice accordingly
– Shape clinical development strategies through insights from local medical practice
– Providing insight and recommended actions linking to the highest value propositions (VP’s) for the affiliate pipeline products and/or new indications.
– Map the relevant TAEs with special focus on active investigators (in PDG countries, where applicable)
– Actively engage with relevant stakeholders (internal and external) to support, inform and shape the ecosystem for new therapeutic areas in collaboration with the GMCLs and/or other functions where applicable and after local prioritization.

– Act as “custodian” of our and competitor data and evidence (in partnership with relevant internal stakeholders) to ensure credible communication of the value of Roche propositions

7. Regulatory Support (Module Regulatory):
– Contribute scientific and medical expertise to the local Regulatory Affairs team to support local Health Authority submissions and interactions to obtain, maintain, and develop product licenses.

Qualification and Experience

Education/Qualifications
– Master Degree or above in Clinical Medicine, Pharma or Bioscience, Clinical Medicine preferred.
– Experience in the therapeutic area is strongly preferred.
– At least 2 years’ pharmaceutical company experience in a medical related role(s). For Bioscience background, at least 3 years’ pharmaceutical company experience in medical related role(s).
Job Required Competencies
– Customer Focus: Prioritizes the needs of patients and customers (HCPs/TAEs), ensuring all actions drive value and satisfaction.
– Strategic Acumen: Ability to think strategically, act with autonomy, and thrive in complex, cross-functional team environments.
– Digital: Basic level of AI literacy and learner mindset that proactively integrates digital tools in day-to-day work. Possesses the knowledge and skills to ensure human in the loop oversight of AI (i.e. Large language models) derived content for internal or external use.
– Collaborative Networker: Collaborates effectively showing leadership, self-motivation and accountability as part of a multi-skilled team (squad) and proactively shares expertise across the organization and across countries to remove silos.
– Growth Mindset & Curiosity: Demonstrates enthusiasm for continuous learning, self-awareness and showing leadership when building a feedback culture. The Medical Partner should be comfortable navigating ambiguity, collaborate and show a strong solution finding mindset.
– Assertive Communication: Excellent ability to articulate complex medical and scientific context, inform medical guidelines by contextualizing our data, build trust, and have conversations in a direct and respectful manner with key stakeholders externally and internally on peer to peer level.
– Entrepreneurial mindset: Takes calculated risks, challenges the status quo, and proposes pragmatic, value adding solutions. The Medical Partner is able to maintain a holistic view of patient, business, and ecosystem needs and does not compromise Roche’s license to operate.
– Value creation: Focusing efforts on the added value, sustainability, and impact brought to patients, customers, and society within the ecosystems, by considering all actions and decisions through the customer and patient lens

Travel Frequency
25% - 50%

Who we are

A healthier future drives us to innovate. Together, more than 100’000 employees across the globe are dedicated to advance science, ensuring everyone has access to healthcare today and for generations to come. Our efforts result in more than 26 million people treated with our medicines and over 30 billion tests conducted using our Diagnostics products. We empower each other to explore new possibilities, foster creativity, and keep our ambitions high, so we can deliver life-changing healthcare solutions that make a global impact.

Let’s build a healthier future, together.

Roche is an Equal Opportunity Employer.